The clinical case for proton beam therapy

Robert L. Foote, Scott L. Stafford, Ivy A Petersen, Jose S Pulido, Michelle J. Clarke, Steven E. Schild, Yolanda Isabel Garces, Kenneth R. Olivier, Robert C. Miller, Michael Haddock, Elizabeth Yan, Nadia N Laack, Carola A.S. Arndt, Steven J. Buskirk, Vickie L. Miller, Christopher R. Brent, Jon J. Kruse, Gary A. Ezzell, Michael G. Herman, Leonard L. Gunderson & 2 others Charles Erlichman, Robert B Diasio

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Over the past 20 years, several proton beam treatment programs have been implemented throughout the United States. Increasingly, the number of new programs under development is growing. Proton beam therapy has the potential for improving tumor control and survival through dose escalation. It also has potential for reducing harm to normal organs through dose reduction. However, proton beam therapy is more costly than conventional x-ray therapy. This increased cost may be offset by improved function, improved quality of life, and reduced costs related to treating the late effects of therapy. Clinical research opportunities are abundant to determine which patients will gain the most benefit from proton beam therapy. We review the clinical case for proton beam therapy.Proton beam therapy is a technically advanced and promising form of radiation therapy.

Original languageEnglish (US)
Article number174
JournalRadiation Oncology
Volume7
Issue number1
DOIs
StatePublished - Oct 22 2012

Fingerprint

Proton Therapy
Costs and Cost Analysis
Protons
Radiotherapy
Therapeutics
Quality of Life
X-Rays
Survival
Research
Neoplasms

Keywords

  • Clinical review
  • Neoplasms
  • Proton beam therapy
  • X-ray therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

The clinical case for proton beam therapy. / Foote, Robert L.; Stafford, Scott L.; Petersen, Ivy A; Pulido, Jose S; Clarke, Michelle J.; Schild, Steven E.; Garces, Yolanda Isabel; Olivier, Kenneth R.; Miller, Robert C.; Haddock, Michael; Yan, Elizabeth; Laack, Nadia N; Arndt, Carola A.S.; Buskirk, Steven J.; Miller, Vickie L.; Brent, Christopher R.; Kruse, Jon J.; Ezzell, Gary A.; Herman, Michael G.; Gunderson, Leonard L.; Erlichman, Charles; Diasio, Robert B.

In: Radiation Oncology, Vol. 7, No. 1, 174, 22.10.2012.

Research output: Contribution to journalArticle

Foote, RL, Stafford, SL, Petersen, IA, Pulido, JS, Clarke, MJ, Schild, SE, Garces, YI, Olivier, KR, Miller, RC, Haddock, M, Yan, E, Laack, NN, Arndt, CAS, Buskirk, SJ, Miller, VL, Brent, CR, Kruse, JJ, Ezzell, GA, Herman, MG, Gunderson, LL, Erlichman, C & Diasio, RB 2012, 'The clinical case for proton beam therapy', Radiation Oncology, vol. 7, no. 1, 174. https://doi.org/10.1186/1748-717X-7-174
Foote, Robert L. ; Stafford, Scott L. ; Petersen, Ivy A ; Pulido, Jose S ; Clarke, Michelle J. ; Schild, Steven E. ; Garces, Yolanda Isabel ; Olivier, Kenneth R. ; Miller, Robert C. ; Haddock, Michael ; Yan, Elizabeth ; Laack, Nadia N ; Arndt, Carola A.S. ; Buskirk, Steven J. ; Miller, Vickie L. ; Brent, Christopher R. ; Kruse, Jon J. ; Ezzell, Gary A. ; Herman, Michael G. ; Gunderson, Leonard L. ; Erlichman, Charles ; Diasio, Robert B. / The clinical case for proton beam therapy. In: Radiation Oncology. 2012 ; Vol. 7, No. 1.
@article{75a586e38c2c4b1d89cbe695cc46419b,
title = "The clinical case for proton beam therapy",
abstract = "Over the past 20 years, several proton beam treatment programs have been implemented throughout the United States. Increasingly, the number of new programs under development is growing. Proton beam therapy has the potential for improving tumor control and survival through dose escalation. It also has potential for reducing harm to normal organs through dose reduction. However, proton beam therapy is more costly than conventional x-ray therapy. This increased cost may be offset by improved function, improved quality of life, and reduced costs related to treating the late effects of therapy. Clinical research opportunities are abundant to determine which patients will gain the most benefit from proton beam therapy. We review the clinical case for proton beam therapy.Proton beam therapy is a technically advanced and promising form of radiation therapy.",
keywords = "Clinical review, Neoplasms, Proton beam therapy, X-ray therapy",
author = "Foote, {Robert L.} and Stafford, {Scott L.} and Petersen, {Ivy A} and Pulido, {Jose S} and Clarke, {Michelle J.} and Schild, {Steven E.} and Garces, {Yolanda Isabel} and Olivier, {Kenneth R.} and Miller, {Robert C.} and Michael Haddock and Elizabeth Yan and Laack, {Nadia N} and Arndt, {Carola A.S.} and Buskirk, {Steven J.} and Miller, {Vickie L.} and Brent, {Christopher R.} and Kruse, {Jon J.} and Ezzell, {Gary A.} and Herman, {Michael G.} and Gunderson, {Leonard L.} and Charles Erlichman and Diasio, {Robert B}",
year = "2012",
month = "10",
day = "22",
doi = "10.1186/1748-717X-7-174",
language = "English (US)",
volume = "7",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The clinical case for proton beam therapy

AU - Foote, Robert L.

AU - Stafford, Scott L.

AU - Petersen, Ivy A

AU - Pulido, Jose S

AU - Clarke, Michelle J.

AU - Schild, Steven E.

AU - Garces, Yolanda Isabel

AU - Olivier, Kenneth R.

AU - Miller, Robert C.

AU - Haddock, Michael

AU - Yan, Elizabeth

AU - Laack, Nadia N

AU - Arndt, Carola A.S.

AU - Buskirk, Steven J.

AU - Miller, Vickie L.

AU - Brent, Christopher R.

AU - Kruse, Jon J.

AU - Ezzell, Gary A.

AU - Herman, Michael G.

AU - Gunderson, Leonard L.

AU - Erlichman, Charles

AU - Diasio, Robert B

PY - 2012/10/22

Y1 - 2012/10/22

N2 - Over the past 20 years, several proton beam treatment programs have been implemented throughout the United States. Increasingly, the number of new programs under development is growing. Proton beam therapy has the potential for improving tumor control and survival through dose escalation. It also has potential for reducing harm to normal organs through dose reduction. However, proton beam therapy is more costly than conventional x-ray therapy. This increased cost may be offset by improved function, improved quality of life, and reduced costs related to treating the late effects of therapy. Clinical research opportunities are abundant to determine which patients will gain the most benefit from proton beam therapy. We review the clinical case for proton beam therapy.Proton beam therapy is a technically advanced and promising form of radiation therapy.

AB - Over the past 20 years, several proton beam treatment programs have been implemented throughout the United States. Increasingly, the number of new programs under development is growing. Proton beam therapy has the potential for improving tumor control and survival through dose escalation. It also has potential for reducing harm to normal organs through dose reduction. However, proton beam therapy is more costly than conventional x-ray therapy. This increased cost may be offset by improved function, improved quality of life, and reduced costs related to treating the late effects of therapy. Clinical research opportunities are abundant to determine which patients will gain the most benefit from proton beam therapy. We review the clinical case for proton beam therapy.Proton beam therapy is a technically advanced and promising form of radiation therapy.

KW - Clinical review

KW - Neoplasms

KW - Proton beam therapy

KW - X-ray therapy

UR - http://www.scopus.com/inward/record.url?scp=84867660663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867660663&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-7-174

DO - 10.1186/1748-717X-7-174

M3 - Article

VL - 7

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 174

ER -